Browse studies

Find your next paid study

12 recruiting studies matching your filters

A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the max…

Central Nervous System NeoplasmsGlioblastomaGliosarcoma, Adult+20 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Jazz PharmaceuticalsNCT04541082

High Resolution Retinal Imaging

Studying the morphology and function of the normal and diseased retina in vivo is needed for advancing the detection, diagnosis, and treatment of retinal disea…

StargardtsRetinitis PigmentosaAge-related Macular Degeneration+2 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of PennsylvaniaNCT01866371

Phase 2

A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as a…

Macular DegenerationAge-Related Macular DegenerationChoroidal Neovascularization+1 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

EyeBiotech Ltd.NCT07496567

A Long-Term Follow-Up Study of Subjects Completing the AU-011-301 (CoMpass) Trial of Bel-sar for Early Choroidal Melanoma (Indeterminate Lesions/Small Choroidal Melanomas)

AU-011-403 is a multicenter long-term follow-up safety and efficacy study of subjects with early CM who previously participated in the AU-011-301 Phase 3 trial…

Choroidal MelanomaIndeterminate Lesions

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Aura BiosciencesNCT07338968

Foundation Fighting Blindness My Retina Tracker Registry

The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative …

Eye Diseases HereditaryRetinal DiseaseAchromatopsia+25 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Foundation Fighting BlindnessNCT02435940

Familial Investigations of Childhood Cancer Predisposition

NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may recei…

Acute LeukemiaAdenomatous PolyposisAdrenocortical Carcinoma+43 more

Estimated

~$10 – $750

Phase 1

An Open Label, Phase 1b Safety, Dose-finding, Brain Tumor Delivery, and Pharmacokinetics Study of Intranasal NEO100 in Patients With Pediatric-type Select Brain Tumors

This is an open label, Phase 1b safety, dose-finding, brain tumor delivery, and pharmacokinetics study of intranasal NEO100 in patients with pediatric-type dif…

Pediatric Tumor of CNSPediatric Tumor of BrainDiffuse Midline Glioma, H3 K27M-Mutant+5 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Neonc Technologies, Inc.NCT06357377

Phase 1

Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4+ and CD8+ T cells lentivirally transduced to express …

Central Nervous System TumorDiffuse Intrinsic Pontine GliomaDiffuse Midline Glioma+8 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Seattle Children's HospitalNCT04185038

Phase 2

A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as a…

Macular DegenerationAge-Related Macular DegenerationChoroidal Neovascularization+1 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

EyeBiotech Ltd.NCT07440225

Observational

Effects of Acute Sugar Intake on Choroidal Thickness

This study aims to bridge that gap by investigating how acute sugar intake influences choroidal thickness.

Choroid

Estimated

~$10 – $750

Actual pay is set by the research site.

Southern College of OptometryNCT07376005

Observational, Non-Interventional Study to Determine the Operational Feasibility and Measurement Properties of Endpoints in Patients with Retinal Degeneration

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with …

Retinitis PigmentosaChoroideremiaStargardt Macular Dystrophy+4 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Ray Therapeutics, Inc.NCT06375239

Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Rare Retinal and Choroidal Diseases

This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and O…

Retinal Artery OcclusionsPolypoidal Choroidal VasculopathyRetinal Arterial Macroaneurysm+2 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Oregon Health and Science UniversityNCT02141308